Guidance for Studies Evaluating the Accuracy of Tuberculosis Triage Tests
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Approximately 3.6 million cases of active tuberculosis (TB) go potentially undiagnosed annually, partly due to limited access to confirmatory diagnostic tests, such as molecular assays or mycobacterial culture, in community and primary healthcare settings. This article provides guidance for TB triage test evaluations. A TB triage test is designed for use in people with TB symptoms and/or significant risk factors for TB. Triage tests are simple and low-cost tests aiming to improve ease of access and implementation (compared with confirmatory tests) and decrease the proportion of patients requiring more expensive confirmatory testing. Evaluation of triage tests should occur in settings of intended use, such as community and primary healthcare centers. Important considerations for triage test evaluation include study design, population, sample type, test throughput, use of thresholds, reference standard (ideally culture), and specimen flow. The impact of a triage test will depend heavily on issues beyond accuracy, primarily centered on implementation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies
Whiting, P. F., Rutjes, A. W. S., Westwood, M. E., Mallett, S., Deeks, J. J., Reitsma, J. B., Leeflang, M. M. G., Sterne, J. A. C., Bossuyt, P. M. M., & the QUADAS-2 Group* (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-8-201110180-00009 · Cited by 14,199
STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies
Bossuyt, P. M., Reitsma, J. B., Bruns, D. E., Gatsonis, C. A., Glasziou, P. P., Irwig, L., Lijmer, J. G., Moher, D., Rennie, D., de Vet, H. C. W., et al. (2015) · BMJ · doi:10.1136/bmj.h5527 · Cited by 3,660 · cited 1×
“[41].”
Rapid Molecular Detection of Tuberculosis and Rifampin Resistance
Boehme, C. C., Nabeta, P., Hillemann, D., Nicol, M. P., Shenai, S., Krapp, F., Allen, J., Tahirli, R., Blakemore, R., Rustomjee, R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907847 · Cited by 2,309 · cited 1×
“…in the development of molecular diagnostic tests for TB. GeneXpert MTB/RIF (Xpert) (Cepheid Inc., Sunnyvale, CA) is a cartridge-based nucleic acid amplification test for rapid diagnosis of TB and rifampicin resistance that was first endorsed by the World Health Organization (WHO) in 2010 [8, 9].”
BackgroundHwang, E. J., Park, S., Jin, K.-N., Kim, J. I., Choi, S. Y., Lee, J. H., Goo, J. M., Aum, J., Yim, J.-J., Park, C. M., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy967 · Cited by 241
Philipsen, R. H. H. M., Sánchez, C. I., Maduskar, P., Melendez, J., Peters-Bax, L., Peter, J. G., Dawson, R., Theron, G., Dheda, K., & van Ginneken, B. (2015) · Scientific Reports · doi:10.1038/srep12215 · Cited by 77 · cited 1×
“09 for patients tested with Xpert alone) and increased throughput from 45 to 113 patients per day [35].”
Background
Research works printed but not linked: 43
- World Health Organization, 2018, Global Tuberculosis Control. WHO Report 2018
- Cheng, 2013, Effect of diagnostic and treatment delay on the risk of tuberculosis transmission in Shenzhen, China: an observational cohort study, 1993-2010, PLoS One, 8, e67516, 10.1371/journal.pone.0067516 · DOI
- Cohen, 2010, The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu-Natal, South Africa: a postmortem study, PLoS Med, 7, e1000296, 10.1371/journal.pmed.1000296 · DOI
- Bates, 2015, Burden of tuberculosis at post mortem in inpatients at a tertiary referral centre in sub-Saharan Africa: a prospective descriptive autopsy study, Lancet Infect Dis, 15, 544, 10.1016/S1473-3099(15)70058-7 · DOI
- Sreeramareddy, 2009, Time delays in diagnosis of pulmonary tuberculosis: a systematic review of literature, BMC Infect Dis, 9, 91, 10.1186/1471-2334-9-91 · DOI · Paper page
- Getnet, 2017, Delay in diagnosis of pulmonary tuberculosis in low-and middle-income settings: systematic review and meta-analysis, BMC Pulm Med, 17, 202, 10.1186/s12890-017-0551-y · DOI · Paper page
- Huddart, 2016, Location, location, location: tuberculosis services in highest burden countries, Lancet Glob Health, 4, e907, 10.1016/S2214-109X(16)30248-0 · doi:10.1016/s2214-109x(16)30248-0
- World Health Organization, 2011, Policy Statement: Automated Real-Time Nucleic Acid Amplification Technology for Rapid and Simultaneous Detection of Tuberculosis and Rifampicin Resistance: Xpert MTB/RIF
- World Health Organization, 2016, Automated Real-Time Nucleic Acid Amplification Technology for Rapid and Simultaneous Detection of Tuberculosis and Rifampicin Resistance: Xpert MTB/RIF Assay for the Diagnosis Of Pulmonary and Extrapulmonary TB in Adults and Children: Policy Update
- World Health Organization, 2018, WHO Meeting Report of a Technical Expert Consultation: Non-inferiority analysis of Xpert MTB/RIF ultra compared to Xpert MTB/RIF
- Albert, 2016, Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better?, Eur Respir J, 48, 516, 10.1183/13993003.00543-2016 · DOI · Paper page
- Theron, 2014, Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial, Lancet, 383, 424, 10.1016/S0140-6736(13)62073-5 · DOI · Paper page
- Médecins Sans Frontières, 2017, Out of Step: TB policies in 29 countries
- Nathavitharana, 2017, Accuracy of line probe assays for the diagnosis of pulmonary TB and detection of resistance to rifampicin and isoniazid: a systematic review and meta-analysis, Eur Respir J, 49, 1601075, 10.1183/13993003.01075-2016 · DOI · Paper page
- Shete, 2019, Diagnostic accuracy of TB-LAMP for pulmonary tuberculosis: a systematic review and meta-analysis, BMC Infect Dis, 19, 268, 10.1186/s12879-019-3881-y · DOI
- FIND diagnostic pipeline
- Bossuyt, 2006, Comparative accuracy: assessing new tests against existing diagnostic pathways, BMJ, 332, 1089, 10.1136/bmj.332.7549.1089 · DOI · Paper page
- World Health Organization, 2014, High-priority target product profiles for new tuberculosis diagnostics: Report of a consensus meeting
- Kik, 2014, Tuberculosis diagnostics: which target product profiles should be prioritised?, Eur Respir J, 44, 537, 10.1183/09031936.00027714 · DOI
- World Health Organization, 2013, Systematic screening for active tuberculosis: Principles and recommendations
- Van’t Hoog, 2014, Choosing algorithms for TB screening: a modelling study to compare yield, predictive value and diagnostic burden, BMC Infect Dis, 14, 532, 10.1186/1471-2334-14-532 · DOI · Paper page
- Chihota, 2015, Missed opportunities for TB investigation in primary care clinics in South Africa: experience from the XTEND trial, PLoS One, 10, e0138149, 10.1371/journal.pone.0138149 · DOI
- Claassens, 2013, Tuberculosis cases missed in primary health care facilities: should we redefine case finding?, Int J Tuberc Lung Dis, 17, 608, 10.5588/ijtld.12.0506 · DOI · Paper page
- Kweza, 2018, Estimating the magnitude of pulmonary tuberculosis patients missed by primary health care clinics in South Africa, Int J Tuberc Lung Dis, 22, 264, 10.5588/ijtld.17.0491 · DOI
- Roy, 2016, Implementation and operational research: use of symptom screening and sputum microscopy testing for active tuberculosis case detection among HIV-infected patients in real-world clinical practice in Uganda, J Acquir Immune Defic Syndr, 72, e86, 10.1097/QAI.0000000000001067 · doi:10.1097/qai.0000000000001067
- MacLean, 2019, Author Correction: a systematic review of biomarkers to detect active tuberculosis, Nat Microbiol, 4, 899, 10.1038/s41564-019-0452-3 · doi:10.1038/s41564-019-0452-3
- Pande, 2016, Computer-aided detection of pulmonary tuberculosis on digital chest radiographs: a systematic review, Int J Tuberc Lung Dis, 20, 1226, 10.5588/ijtld.15.0926 · DOI · Paper page
- Barrera, 2015, F-A-S-T: a refocused, intensified, administrative tuberculosis transmission control strategy, Int J Tuberc Lung Dis, 19, 381, 10.5588/ijtld.14.0680 · doi:10.5588/ijtld.14.0680
- Nathavitharana, 2017, FAST implementation in Bangladesh: high frequency of unsuspected tuberculosis justifies challenges of scale-up, Int J Tuberc Lung Dis, 21, 1020, 10.5588/ijtld.16.0794 · DOI
- Yoon, 2019, Screening for tuberculosis: time to move beyond symptoms, Lancet Respir Med, 7, 202, 10.1016/S2213-2600(19)30039-6 · DOI
- Ahmad Khan, 2017, Computer-aided reading of tuberculosis chest radiography: moving the research agenda forward to inform policy, Eur Respir J, 50, 10.1183/13993003.00953-2017 · DOI · Paper page
- Yoon, 2017, Diagnostic accuracy of C-reactive protein for active pulmonary tuberculosis: a meta-analysis, Int J Tuberc Lung Dis, 21, 1013, 10.5588/ijtld.17.0078 · DOI
- Yoon, 2017, Point-of-care C-reactive protein-based tuberculosis screening for people living with HIV: a diagnostic accuracy study, Lancet Infect Dis, 17, 1285, 10.1016/S1473-3099(17)30488-7 · DOI
- Chegou, 2016, Diagnostic performance of a seven-marker serum protein biosignature for the diagnosis of active TB disease in African primary healthcare clinic attendees with signs and symptoms suggestive of TB, Thorax, 71, 785, 10.1136/thoraxjnl-2015-207999 · DOI
- De Groote, 2017, Discovery and validation of a six-marker serum protein signature for the diagnosis of active pulmonary tuberculosis, J Clin Microbiol, 55, 3057, 10.1128/JCM.00467-17 · DOI
- Phillips, 2012, Point-of-care breath test for biomarkers of active pulmonary tuberculosis, Tuberculosis (Edinb), 92, 314, 10.1016/j.tube.2012.04.002 · DOI · Paper page
- Nliwasa, 2018, High HIV and active tuberculosis prevalence and increased mortality risk in adults with symptoms of TB: a systematic review and meta-analyses, J Int AIDS Soc, 21, e25162, 10.1002/jia2.25162 · DOI
- Datiko, 2019, Sub-national prevalence survey of tuberculosis in rural communities of Ethiopia, BMC Public Health, 19, 295, 10.1186/s12889-019-6620-9 · doi:10.1186/s12889-019-6620-9
- Leeflang, 2008, Bias in sensitivity and specificity caused by data-driven selection of optimal cutoff values: mechanisms, magnitude, and solutions, Clin Chem, 54, 729, 10.1373/clinchem.2007.096032 · DOI · Paper page
- World Health Organization, 2007, Policy statement: liquid media for culture and DST
- Esmail, 2016, Characterization of progressive HIV-associated tuberculosis using 2-deoxy-2-[18F]fluoro-D-glucose positron emission and computed tomography, Nat Med, 22, 1090, 10.1038/nm.4161 · DOI · Paper page
- Schumacher, 2016, Diagnostic test accuracy in childhood pulmonary tuberculosis: a Bayesian latent class analysis, Am J Epidemiol, 184, 690, 10.1093/aje/kww094 · DOI · Paper page
- Yoon, 2019, Yield and efficiency of novel intensified tuberculosis case-finding algorithms for people living with HIV, Am J Respir Crit Care Med, 199, 643, 10.1164/rccm.201803-0490OC · DOI
Cited by
Qin, Z. Z., Ahmed, S., Sarker, M. S., Paul, K., Adel, A. S. S., Naheyan, T., Barrett, R., Banu, S., & Creswell, J. (2021) · The Lancet Digital Health · doi:10.1016/s2589-7500(21)00116-3 · Cited by 290
Khan, F. A., Majidulla, A., Tavaziva, G., Nazish, A., Abidi, S. K., Benedetti, A., Menzies, D., Johnston, J. C., Khan, A. J., & Saeed, S. (2020) · The Lancet Digital Health · doi:10.1016/s2589-7500(20)30221-1 · Cited by 134
Fehr, J., Konigorski, S., Olivier, S., Gunda, R., Surujdeen, A., Gareta, D., Smit, T., Baisley, K., Moodley, S., Moosa, Y., et al. (2021) · npj Digital Medicine · doi:10.1038/s41746-021-00471-y · Cited by 74
“…applicable threshold would be useful, several studies have suggested that threshold selection should be adjusted according to the factors unique to each setting, including the underlying TB prevalence, demographic parameters, type, and number of available microbiological tests 12,19,20 .”
BackgroundMacPherson, P., Webb, E. L., Kamchedzera, W., Joekes, E., Mjoli, G., Lalloo, D. G., Divala, T. H., Choko, A. T., Burke, R. M., Maheswaran, H., et al. (2021) · PLOS Medicine · doi:10.1371/journal.pmed.1003752 · Cited by 69
Self-citationVanobberghen, F., Keter, A. K., Jacobs, B. K. M., Glass, T. R., Lynen, L., Law, I., Murphy, K., van Ginneken, B., Ayakaka, I., van Heerden, A., et al. (2024) · ERJ Open Research · doi:10.1183/23120541.00508-2023 · Cited by 13
“…tuberculosis prevalence survey to determine a CAD4TB version 7 (CAD4TBv7) threshold for use in the trial, meeting the WHO minimum target product profile criteria for screening and diagnostic algorithms of >90% sensitivity, and preferably >70% specificity, using nonsputum based rapid tests [32, 33].”
Self-citation
Metadata
- Authors
- Nathavitharana, R. R., Yoon, C., Macpherson, P., Dowdy, D. W., Cattamanchi, A., Somoskovi, A., Broger, T., Ottenhoff, T. H. M., Arinaminpathy, N., Lonnroth, K., Reither, K., Cobelens, F., Gilpin, C., Denkinger, C. M., & Schumacher, S. G.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-10-08
- Volume
- 220
- Issue
- Supplement_3
- Pages
- S116-S125
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2979533273
- Cited by
- 45
- References
- 5
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Funders
- National Institute of Allergy and Infectious Diseases (K23 AI13264801A1)
- American Society of Tropical Medicine and Hygiene
- Harvard Center for AIDS Research Scholar Award (2P30AI060354-11)
- National Institutes of Health (K23 AI114363)
- Wellcome Trust (206575)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Guidance for Studies Evaluating the Accuracy of Tuberculosis Triage Tests. https://app.cochat.ai/papers/10.1093/infdis/jiz243
- The paper
- Nathavitharana, R. R., Yoon, C., Macpherson, P., Dowdy, D. W., Cattamanchi, A., Somoskovi, A., Broger, T., Ottenhoff, T. H. M., Arinaminpathy, N., Lonnroth, K., Reither, K., Cobelens, F., Gilpin, C., Denkinger, C. M., & Schumacher, S. G. (2019). Guidance for Studies Evaluating the Accuracy of Tuberculosis Triage Tests. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiz243
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.